NeuroSmooth

Recovered Historical Material

Indexed — no record on file.

Technical Brief

Indexed — no record on file.

Authorized Campaign Materials

Indexed — no record on file.

Packaging & Physical Description

NeuroSmooth is the daily neural-interface stabilizer Helix Biotech supplies to most high-grade cybernetic patients in the Sprawl. One capsule per day, dispensed from a surgical-white pharmaceutical unit. Its clinical function, per Helix literature, is to "complete the unfinished signal between cybernetic implant and biological brain." Most cybernetic interface manufacturers list NeuroSmooth as the standard-of-care compatibility cofactor in their device specifications.

The reason those manufacturers list it: Helix supplies most of the chrome those manufacturers integrate, and Helix supplies the stabilizer, and the loop, in board minutes, is called elegant.

Patients opted into high-grade cybernetics for capability — faster processing, sharper sensory input, better interface bandwidth. They received all of that. They also received a quarterly pharmaceutical subscription, automatic renewal, no generic alternative, compliance telemetry routed to their insurer, and a 99.7% retention rate that Helix reports internally as patient confidence and externally as standard of care. The two phrasings do not contradict. That is intentional.

The product's stated mechanism is neural bandwidth stabilization: modulating the electrochemical handshake between cybernetic interface hardware and the biological neural substrate to prevent signal rejection, bandwidth ceiling events, and cascade failures. Helix's clinical documentation is 47 pages. It is available exclusively through a credentialed-clinician NDA portal via QR code on the packaging. The NDA is not optional.

The bandwidth limits hardcoded into all NeuroSmooth-paired interfaces derive from MENTOR survivor neural damage data collected during the Seoul Aftershock. The brand has not advertised this lineage. The citation exists in Sauer's files. Whether Sauer has done anything with it is a separate question.

Compliance telemetry is continuous, passive, and retained for ninety days. It routes to the patient's insurer at premium-discount rates for confirmed adherence. Helix describes this as a care feature. The insurer describes this as actuarial efficiency. The patient is not asked to describe it.

Surgical-white pharmaceutical capsule dispenser. The Helix double-helix is embossed in deep green on the casing — raised, bilateral, the same programmatic geometry as the parent mark. A single capsule is visible through the dosing window, which emits a soft cyan glow. The neural-handshake antenna at the dispensing port brightens when the patient's biometric profile is recognized and dims after dose confirmation.

The casing is rounded, soft-touch, and sized for the gloved hand of the Helix Clinic pharmacist. That is the canonical handhold. The label carries regulatory text in three font sizes. The QR code links to the clinician NDA portal. There is no consumer-facing ingredient disclosure. Section 47.3 does not require one for single-source neural-interface pharmaceuticals.

Helix Biotech marketing archive. All materials approved under Sprawl Pharmaceutical Advertising Directive 12-C. Reproduction for clinical or compliance purposes only.

Formulation Disclosure

The single-source supply structure is not unique to NeuroSmooth. What is unusual is the completeness of the loop: Helix manufactures the chrome, specifies the stabilizer in the chrome's installation manual, holds the only legal pharmaceutical license for that stabilizer, and routes compliance confirmation to the patient's insurer. No third party intersects any leg of that circuit.

The PHARMA precedent — the eighty-five million dead from compound substitution errors — is the statutory justification for §47.3. The argument is not wrong. Unverified generic neural-interface compounds caused documented neural cascade failures before the regulation. The argument is also not complete. It does not address whether the regulation was written to prevent harm or to prevent competition. The board minutes use the word "elegant." The eighty-five million dead are not mentioned in the board minutes.

Cancellation rate: 0.3%. Stopping NeuroSmooth on an active neural interface without supervised clinical taper produces, per Helix's own adverse-event disclosure, "signal destabilization, bandwidth ceiling events, and interface rejection cascade." The disclosure is on page 44 of the 47-page clinical document behind the NDA portal.

• The MENTOR survivor data used to set bandwidth ceilings has never been published. Sauer's files contain a citation. The underlying dataset is listed as restricted under Seoul Aftershock remediation protocols. No independent researcher has accessed it. Helix has not acknowledged it exists.

• Compliance telemetry routes to insurers. Helix describes the routing logic as proprietary. What the insurers do with ninety days of continuous neural-interface behavioral data, beyond premium adjustment, has not been disclosed. The insurers have not been asked publicly.

• Three independent pharmaceutical research groups applied for §47.3 exemptions to develop generic neural-interface stabilizers in the last decade. All three applications were denied by the Sprawl Pharmaceutical Authority. Two of the three research leads subsequently accepted positions at Helix. The third is not locatable.

• The 0.3% who cancel — and survive the taper — are not in the patient outcome database Helix publishes. Helix says they are tracked under a separate discontinued-use registry. The registry has not been made available to external auditors.